DEF: Cellectar Biosciences Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Cellectar Biosciences is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Cellectar Biosciences is holding its 2025 Annual Meeting of Stockholders virtually on June 13, 2025.
• The meeting will include votes on the election of two Class II directors, ratification of Deloitte & Touche, LLP as the independent accounting firm, and a proposal to approve a reverse stock split.
• The reverse stock split would be at a ratio between 1:10 and 1:30, if and when determined by the Board of Directors.
• Stockholders will also vote on executive compensation and a proposal to adjourn the meeting if necessary to solicit additional proxies for the reverse stock split.
• The Board recommends voting FOR all proposals.
• The record date for voting is April 17, 2025.
• The company received a deficiency letter from Nasdaq because the company's stock price closed below the minimum bid price of $1.00 per share for 30 consecutive business days.
• The company has until July 29, 2025, to regain compliance.

Sentiment

Score: 5

Explanation: The document is primarily procedural, outlining proposals for a stockholder vote. The need for a reverse stock split indicates underlying financial challenges, but the company is taking steps to address them.

Positives

• The Board is taking proactive steps to address the Nasdaq minimum bid price deficiency.
• The company is providing stockholders with multiple avenues to vote (internet, telephone, mail).
• The company is making proxy materials available electronically to reduce environmental impact and costs.
• The company has engaged Alliance Advisors, LLC, to assist in the solicitation of proxies and provide related advice and informational support.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement.
• A reverse stock split could negatively impact investor perception and liquidity.
• There is no guarantee that the reverse stock split will increase the stock price or maintain Nasdaq listing.
• The company incurred a net loss of $44,581,446 for 2024.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• A reverse stock split may not increase the stock price or maintain listing compliance.
• The market price of the common stock could decline, and the percentage decline as an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of a reverse stock split.
• Delisting from Nasdaq could make it more difficult for investors to dispose of or obtain accurate quotations for the company's stock.
• If the stock price falls below $5.00, it could be classified as a penny stock, leading to additional sales practice requirements and reduced trading activity.

Future Outlook

The company intends to seek an extension from Nasdaq to regain compliance with the minimum bid price rule and is considering alternatives to the reverse stock split.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices, but their success is not guaranteed and can sometimes negatively impact investor perception.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges, such as a low stock price and potential delisting, have considered or implemented reverse stock splits.
• Comparable companies that have recently undergone reverse stock splits include but are not limited to: XOMA Corporation (2017), BioDelivery Sciences International (2019), and Diffusion Pharmaceuticals Inc. (2023).
• The success of a reverse stock split in maintaining listing and improving stock price varies widely depending on the company's underlying fundamentals and market conditions.

Related Party Transactions

• On September 5, 2023, the Company entered into a securities purchase agreement with certain accredited investors, including ADAR1 Partners, LP, certain entities associated with AIGH Capital Management LLC, Laurence W. Lytton, certain entities associated with Nantahala Capital Management, LLC and certain entities associated with Rosalind Advisors, Inc., pursuant to which the Company agreed to issue and sell, in a private placement, (i) 1,225 shares of Series E-1 Convertible Voting Preferred Stock, par value $0.00001 per share (the Series E-1 Preferred Stock), (ii) Tranche A Warrants (the Tranche A Warrants) to acquire shares of Series E-3 Convertible Voting Preferred Stock and (iii) Tranche B Warrants (the Tranche B Warrants, together with the Tranche A Warrants, the Warrants) to acquire shares of Series E-4 Convertible Voting Preferred Stock, par value $0.00001 per share (the Series E-4 Preferred Stock and together with the Series E-3 Preferred Stock, the Warrant Shares) for an aggregate offering price of $24.5 million.
• ADAR1 Partners, LP, AIGH Capital Management LLC, Laurence W. Lytton, Nantahala Capital Management, LLC and Rosalind Advisors, Inc. are beneficial owners of more than 5% of our outstanding capital stock.
• On July 21, 2024, the Company entered into warrant exercise inducement offer letters (the Inducement Letters) with certain accredited investors, including ADAR1 Partners, LP, certain entities associated with AIGH Capital Management LLC, Laurence W. Lytton, certain entities associated with Nantahala Capital Management, LLC, certain entities associated with Kingsbrook Partners LP, Triple Gate Partners, LP, Bigger Capital Fund, LP, District 2 Capital Fund, LP, Healthcare Opportunities Master Fund, LP, The Hewlett Fund, LP and certain entities associated with Rosalind Advisors, Inc., who are holders of the Tranche B Warrants, which were originally issued on September 8, 2023, pursuant to which such holders agreed to exercise for cash their Tranche B Warrants to purchase an amount of shares of the Series E-4 Preferred Stock which is convertible to 6,739,918 shares of the Companys common stock, in the aggregate, at a reduced, as-converted common stock exercised price of $2.52 per share, in exchange for the Companys agreement to issue new warrants.

Stakeholder Impact

• Stockholders: The reverse stock split could impact the value and liquidity of their shares.
• Employees: A higher stock price could help attract and retain employees.
• Investors: The reverse stock split could affect the marketability and acceptance of the stock by institutional investors.

Next Steps

• Stockholder vote on the proposals at the Annual Meeting on June 13, 2025.
• Board decision on whether to implement the reverse stock split, and at what ratio, if approved by stockholders.
• Company to seek an extension from Nasdaq to regain compliance with the minimum bid price rule.
• Filing of an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware if the Board determines to proceed with the reverse stock split.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, Nasdaq, Deloitte, executive compensation, directors, stockholders, compliance, listing